<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Jbio — News on 6ix</title>
    <link>https://6ix.com/company/jbio</link>
    <description>Latest news and press releases for Jbio on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 23 Apr 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/jbio" rel="self" type="application/rss+xml" />
    <item>
      <title>Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-announces-inducement-grant-under-nasdaq-listing-rule-5635c4</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-announces-inducement-grant-under-nasdaq-listing-rule-5635c4</guid>
      <pubDate>Thu, 23 Apr 2026 11:00:00 GMT</pubDate>
      <description>SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that Jade’s Board of Directors granted an equity award to Edward R. Conner, M.D., effective as of April 22, 2026, in connection with his appointment as Chief Medical Officer. The Board of Directors granted Dr. Conner non-qualif</description>
    </item>
    <item>
      <title>Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-appoints-edward-r-conner-md-as-chief-medical-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-appoints-edward-r-conner-md-as-chief-medical-officer</guid>
      <pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
      <description>SAN FRANCISCO and VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Edward R. Conner, M.D., as Chief Medical Officer (CMO), effective today. Dr. Conner is an accomplished biopharmaceutical executive with extensive experience spanning clinical development, translational medici</description>
    </item>
    <item>
      <title>Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update-12</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update-12</guid>
      <pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
      <description>JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to</description>
    </item>
    <item>
      <title>Jade Biosciences to Participate in Upcoming Conferences</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-participate-upcoming-conferences-120000047</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-participate-upcoming-conferences-120000047</guid>
      <pubDate>Wed, 11 Feb 2026 12:00:00 GMT</pubDate>
      <description>SAN FRANCISCO and VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference | February 25-26, 2026Presentation: Thursday, February 26 at 1:20 p.m. ET |Track 3TD Cowen 46th Annual Health Care Conference | March 2-4, 202</description>
    </item>
    <item>
      <title>Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-outlines-key-2026-120000719</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-outlines-key-2026-120000719</guid>
      <pubDate>Mon, 05 Jan 2026 12:00:00 GMT</pubDate>
      <description>JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid-2026; preliminary data anticipated in 2027JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human study in rheumatoid arthritis patients in the second quarter of 2026; interim data anticipated in 2027Third development candidate, JADE301, nomin</description>
    </item>
    <item>
      <title>Jade Biosciences Announces $45 Million Private Placement</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-announces-45-million-120000840</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-announces-45-million-120000840</guid>
      <pubDate>Mon, 15 Dec 2025 12:00:00 GMT</pubDate>
      <description>SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement with BB Biotech for a private placement financing that is expected to result in gross proceeds of approximately $45 million to the Company, before offering expenses. Purs</description>
    </item>
    <item>
      <title>Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-reports-third-quarter-210500719</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-reports-third-quarter-210500719</guid>
      <pubDate>Thu, 13 Nov 2025 21:05:00 GMT</pubDate>
      <description>Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at the American Society of Nephrology Kidney Week 2025, reinforcing its potential as a best-in-class selective anti-APRIL monoclonal antibody for IgA nephropathy Initiated Phase 1 healthy volunteer study of JADE101; interim, biomarker-rich data expected in the first half of 2026 are anticipated to define dose and dose interval selection for patient trials Unveiled JADE201, a</description>
    </item>
    <item>
      <title>Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-presents-data-demonstrating-160000794</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-presents-data-demonstrating-160000794</guid>
      <pubDate>Sat, 08 Nov 2025 16:00:00 GMT</pubDate>
      <description>SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today presented two posters for JADE101, its investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A nephropathy (IgAN), at the American Society of Nephrology (ASN) Kidney Week 202</description>
    </item>
    <item>
      <title>Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-announces-data-presentations-200500329</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-announces-data-presentations-200500329</guid>
      <pubDate>Fri, 17 Oct 2025 20:05:00 GMT</pubDate>
      <description>Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding its clinical development in IgA nephropathyJADE101 is an investigational, potentially best-in-class disease-modifying anti-APRIL monoclonal antibody, with a Phase 1 healthy volunteer study underway SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on devel</description>
    </item>
    <item>
      <title>Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-announces-jade201-potentially-110500612</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-announces-jade201-potentially-110500612</guid>
      <pubDate>Tue, 07 Oct 2025 11:05:00 GMT</pubDate>
      <description>JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less frequent subcutaneous dosing JADE201’s high affinity binding and extended half-life enabled dose-dependent BAFF receptor occupancy and sustained B cell depletion in non-human primatesFirst-in-human trial in rheumatoid arthritis expected to begin in the first half of 2026; potentia</description>
    </item>
    <item>
      <title>Jade Biosciences Announces $135 Million Private Placement</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-announces-135-million-110000547</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-announces-135-million-110000547</guid>
      <pubDate>Tue, 07 Oct 2025 11:00:00 GMT</pubDate>
      <description>SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $135 million to the Company, before placement a</description>
    </item>
    <item>
      <title>Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-announces-first-cohort-110000963</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-announces-first-cohort-110000963</guid>
      <pubDate>Tue, 02 Sep 2025 11:00:00 GMT</pubDate>
      <description>Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trialsJADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic profile preclinically, supporting the potential for patient-friendly subcutaneous dosing every eight weeks or longerInterim, biomarker-rich Phase 1 healthy volunteer data are expected in the first half of 2026, and are anticipated to define dose and dosing interval selection based on biomarker respon</description>
    </item>
    <item>
      <title>Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-reports-second-quarter-200500864</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-reports-second-quarter-200500864</guid>
      <pubDate>Wed, 13 Aug 2025 20:05:00 GMT</pubDate>
      <description>Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy-volunteer study of JADE101 expected to begin in the third quarter of 2025, with interim, biomarker-rich data anticipated in the first half of 2026 $220.9 million cash and cash equivalents as of June 30, 2025 supports cash runway through 2027, including multiple clinical inflection points SAN FRANCI</description>
    </item>
    <item>
      <title>Jade Biosciences to Participate in Two Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-participate-two-upcoming-110000479</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-participate-two-upcoming-110000479</guid>
      <pubDate>Tue, 08 Jul 2025 11:00:00 GMT</pubDate>
      <description>SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in two upcoming investor conferences. Jade’s Chief Executive Officer, Tom Frohlich, and Chief Scientific Officer and Head of R&amp;D, Andrew King, BVMS, Ph.D., will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual</description>
    </item>
    <item>
      <title>Jade Biosciences Appoints Brad Dahms as Chief Financial Officer</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-appoints-brad-dahms-110000030</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-appoints-brad-dahms-110000030</guid>
      <pubDate>Tue, 01 Jul 2025 11:00:00 GMT</pubDate>
      <description>SAN FRANCISCO and VANCOUVER, British Columbia, July 01, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Brad Dahms as Chief Financial Officer. “Brad is a proven strategic and financial leader with a strong track record guiding biotech companies through multiple phases of growth,” said Tom Frohlich, Chief Executive Officer of Jade Biosciences.</description>
    </item>
    <item>
      <title>Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-presents-jade101-preclinical-110000911</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-presents-jade101-preclinical-110000911</guid>
      <pubDate>Mon, 09 Jun 2025 11:00:00 GMT</pubDate>
      <description>Preclinical data highlighted JADE101’s femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 showed a differentiated pharmacokinetic and pharmacodynamic profile with deep and sustained IgA reductions and the potential to support convenient subcutaneous dosing every eight weeks or longer First-in-human trial expected to begin second half 2025; biomarker-rich interim data in healthy volunteers</description>
    </item>
    <item>
      <title>Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-present-preclinical-data-110000358</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-present-preclinical-data-110000358</guid>
      <pubDate>Mon, 02 Jun 2025 11:00:00 GMT</pubDate>
      <description>Company to host conference call and webcast on June 9, 2025, at 8:00 a.m. ETSAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical data on JADE101, its anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), will be presented in an oral session during the 62nd Eu</description>
    </item>
    <item>
      <title>Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-reports-first-quarter-200500832</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-reports-first-quarter-200500832</guid>
      <pubDate>Wed, 14 May 2025 20:05:00 GMT</pubDate>
      <description>Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to enter the clinic in second half of 2025, with interim biomarker-rich data expected in first half of 2026 SAN FRANCISCO and VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies</description>
    </item>
    <item>
      <title>Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference</title>
      <link>https://6ix.com/company/jbio/news/jade-biosciences-participate-2025-jefferies-110000485</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/jade-biosciences-participate-2025-jefferies-110000485</guid>
      <pubDate>Tue, 13 May 2025 11:00:00 GMT</pubDate>
      <description>SAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the Jefferies Global Healthcare Conference, June 3-5, 2025, in New York. Tom Frohlich, Chief Executive Officer of Jade, will deliver a company presentation on Wednesday, June 4 at 4:55-5:25 p.m. ET. Members of the management team will also</description>
    </item>
    <item>
      <title>Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals</title>
      <link>https://6ix.com/company/jbio/news/aerovate-therapeutics-stockholders-approve-proposed-merger-with-jade-biosciences-and-all-related-proposals</link>
      <guid isPermaLink="true">https://6ix.com/company/jbio/news/aerovate-therapeutics-stockholders-approve-proposed-merger-with-jade-biosciences-and-all-related-proposals</guid>
      <pubDate>Mon, 21 Apr 2025 04:00:00 GMT</pubDate>
      <description>—Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE)</description>
    </item>
  </channel>
</rss>